Interactive Transcript
0:01
There are some areas of anatomy that I really
0:04
enjoy, and salivary glands are part of the anatomy
0:10
and pathology that is quite refreshing in
0:12
neuroradiology and head-neck imaging.
0:15
And I like the Salivary glands because they have
0:17
a wide variety of both benign
0:19
and malignant neoplasms.
0:21
If you do something like the carotid space,
0:24
basically, the carotid space is dominated 95% of the
0:27
time by benign tumors, those being
0:30
schwannomas and paragangliomas.
0:32
But with salivary gland imaging, you have a wide
0:35
variety of neoplasms and the rate at which
0:39
there is cancer versus benign tumor.
0:42
Malignancies versus benign tumors varies
0:45
from one gland to the other.
0:47
We're going to start off talking about
0:48
the benign neoplasms first.
0:55
Now we have an 80% rule that we talk about with
0:59
regard to salivary gland pathology, and that is
1:02
that 80% of salivary gland tumors
1:05
occur in the parotid gland.
1:09
We say that 80% of parotid
1:12
gland tumors are benign.
1:17
80% of the benign tumors are pleomorphic adenomas.
1:23
And 80% of pleomorphic adenomas do
1:26
Does not show malignant degeneration.
1:33
80% overall of salivary gland tumors are benign.
1:38
So?
1:40
This is the 80% rule.
1:44
What does this mean?
1:45
This means that there are tumors that occur
1:48
outside the parotid gland in the sublingual glands,
1:51
and the submandibular glands, but
1:53
they're pretty uncommon.
1:57
One thing that I will point out is that the 80%
2:01
benign rule generally refers to parotid tumors.
2:05
Elsewhere, there is a higher rate of malignancy.
2:09
So?
2:11
Beware of that.
2:15
Jatin Shaw wrote a really beautiful
2:18
book called Head Neck Surgery.
2:22
This is from the second edition.
2:23
I think he's up to like the fifth edition.
2:25
So this was way back in 1996, but the numbers
2:28
really haven't changed that much.
2:30
This is looking at malignancy, I'm sorry,
2:34
neoplasms of the salivary glands,
2:38
of the major salivary glands, and you can see that
2:41
the vast majority of them are located in the
2:44
parotid gland, followed by the submandibular
2:47
gland, followed by minor salivary glands.
2:51
And these submandibular gland,
2:52
Sublingual gland often are combined together.
2:58
This is a very port.
3:00
Slide.
3:01
This is again from Jatin Shaw's book, and it looks.
3:05
At the rate at which you have benign.
3:09
Versus malignant tumors.
3:10
Remember that we said the 80% rule was that.
3:14
In the parotid gland, 80% are benign.
3:17
Here in Jatin Shaw's experience at the.
3:19
Memorial Stone Kettering Institute.
3:22
It was 75% benign and only 25% malignant.
3:27
80% rule applies in general.
3:31
Obviously, at Memorial Slung Kettering.
3:33
They tend to get referrals for more.
3:35
Malignancies to Slung Kettering.
3:40
Minor Salivary gland tumors.
3:43
You can see are dominated by malignancies.
3:48
So if we think of 80% rule of the Memorial.
3:51
Sloan Kettering experience.
3:53
They would say that 80% of minor salivary.
3:57
Gland tumors are malignant.
4:01
When you look at the sum mandibular and sublingual.
4:03
Glandular tissue, the rate is about 50% 50 50.
4:09
This leads to the adage that the larger the gland.
4:15
The higher the rate of benign tumors.
4:17
So the minor salivary gland tissue that's.
4:21
Microscopic, almost submilli.
4:24
So, the larger the gland, for example,
4:27
the parotid gland, 80% benign.
4:31
Then we go to sublingual and submandibular
4:33
glands, about 50% benign.
4:36
But when we go to the minor salivary gland,
4:38
only about 20% benign. The larger the gland,
4:42
the higher the rate of benign tumors.
4:44
The smaller the gland,
4:46
the higher the rate of malignant tumors.
4:52
Let's start with the parotid gland.
4:55
The parotid gland 80% rule says that 80% of
4:59
the parotid gland neoplasms are benign.
5:03
And of the benign neoplasms of the parotid gland,
5:07
80% are pleomorphic adenomas.
5:10
If you do a simple calculation,
5:12
you'd figure out that 64% (80% times 80%) of parotid
5:18
gland tumors are pleomorphic adenomas.
5:24
Hemangiomas.
5:26
And by these, I mean the congenital hemangiomas or
5:29
the infantile hemangiomas that occur in the parotid
5:34
gland as probably the second most
5:36
common of the benign neoplasms.
5:39
But they are occurring in children
5:41
and they may involute.
5:45
This is different than the venous vascular
5:48
malformation, which we don't consider a neoplasm.
5:50
We're talking about the true neoplasms,
5:53
the hemangiomas that have a growth
5:55
phase and an involution phase
5:59
in adults.
6:00
The second most common parotid gland benign
6:02
neoplasm is the Wharton's tumor.
6:04
And I warned you about Wharfin's
6:06
tumor versus Wharton's duct.
6:09
And then we have the less common oncocytomas,
6:13
schwannomas, and lipomas. I'm not listing here.
6:16
Monomorphic adenomas.
6:18
Those are also benign neoplasms, and
6:22
I'll show some examples of them.
6:29
Let's move to pleomorphic adenomas.
6:32
Pleomorphic adenomas are the most common
6:34
benign salivary gland tumor.
6:37
They are the most common benign parotid tumor.
6:41
They are the most common benign
6:43
submandibular tumor.
6:45
They are the most common benign sublingual tumor
6:49
and they are the most common benign
6:51
minor salivary gland tumor.
6:52
So, pleomorphic adenomas dominate the benign tumors
6:56
in all of the different types of salivary gland.
7:01
By and large,
7:02
the pleomorphic adenomas are sort of the
7:04
meningiomas of the brain in that demographically.
7:08
They occur in relatively young women, 30 to
7:11
50 years old, and women more so than men.
7:15
Usually two to one,
7:17
maybe two and a half to one ratio.
7:21
Their imaging feature, which is characteristic,
7:23
is that they are bright on T2-weighted imaging.
7:27
And that's what we look for.
7:29
Bright signal on T2-weighted imaging.
7:31
However, they may have calcification,
7:33
they may have fat, they may have cysts within them.
7:36
So there is some heterogeneity
7:39
to the pleomorphic adenoma,
7:41
not as much as what we see with Wharton's tumors.
© 2024 Medality. All Rights Reserved.